Fresh from announcing a huge $9 billion takeover of CAR-T cell therapy specialist Juno Therapeutics, Celgene (Nasdaq: CELG) has announced better-than-predicted results for the last quarter of 2017.
The US biotech group reported adjusted earnings-per-share of $2 and revenues of $3.48 billion, beating Wall Street estimates of $1.97 and $3.46 billion respectively.
Both the quarterly revenue figure and the total for 2017 as a whole – of $13 billion – represent rises of around 16% to 17% compared to the previous year, with Revlimid (lenalidomide), which provides 60% of Celgene’s sales, responsible for much of the growth.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze